General MedicationsINHALATIONStandard
TYVASO
TREPROSTINIL
Standard Dose
0.6MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview TYVASO is listed in Drugs@FDA under application 022387 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL Form and strength SOLUTION;INHALATION - 0.6MG/ML Sponsor UNITED THERAP Submission history Latest submission status date: 2022-05-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview TYVASO is listed in Drugs@FDA under application 022387 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL Form and strength SOLUTION;INHALATION - 0.6MG/ML Sponsor UNITED THERAP Submission history Latest submission status date: 2022-05-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.